Tiziana Life Sciences will present its immunomodulation therapies, highlighting intranasal foralumab, at the Jefferies London Healthcare Conference.
Quiver AI Summary
Tiziana Life Sciences, Ltd., a biotechnology company focused on immunomodulation therapies, announced that its senior leadership will present at the Jefferies London Healthcare Conference on November 19, 2025. CEO Ivor Elrifi and COO/CFO Keeren Shah will provide a corporate overview of the company’s innovative pipeline, including updates on their lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody being studied for neurodegenerative diseases like multiple sclerosis and Alzheimer's. Tiziana’s participation in this major investor forum highlights its increasing visibility and commitment to developing transformative therapies for unmet medical needs. The presentation will include insights from ongoing clinical trials, demonstrating the potential of intranasal foralumab to improve treatment efficacy and safety.
Potential Positives
- Tiziana Life Sciences' participation in the prestigious Jefferies London Healthcare Conference highlights its growing visibility and credibility within the biotechnology investment community.
- The presentation will focus on Tiziana's innovative pipeline, particularly its lead candidate, intranasal foralumab, which is unique as the only fully human anti-CD3 monoclonal antibody in clinical development for neurodegenerative diseases.
- The positive initial results from the Expanded Access Program for foralumab, showing improvement or stability of disease in all 14 patients treated within 6 months, bolsters the company's position in the market and its promise for future therapies.
- Tiziana's innovative delivery method for immunotherapy via intranasal administration may offer enhanced efficacy, safety, and tolerability compared to traditional intravenous methods, positioning the company favorably against competitors.
Potential Negatives
- The press release does not provide substantial new data or compelling results regarding the clinical efficacy of foralumab, potentially leading to skepticism among investors and stakeholders.
- Limited patient data from the open-label program (14 patients) may raise concerns about the scalability and robustness of the treatment results, which might affect investor confidence.
- The company's focus on a single lead candidate, foralumab, may expose it to significant risks if the drug underperforms or encounters development hurdles.
FAQ
What is Tiziana Life Sciences' lead candidate?
Tiziana's lead candidate is intranasal foralumab, a fully human anti-CD3 monoclonal antibody for treating neurodegenerative diseases.
When will Tiziana present at the Jefferies London Healthcare Conference?
Tiziana will present on November 19, 2025, from 12:30 p.m. to 12:55 p.m. GMT.
What diseases does foralumab target?
Foralumab targets non-active secondary progressive multiple sclerosis, Alzheimer’s disease, multiple system atrophy, and amyotrophic lateral sclerosis.
How is foralumab administered?
Foralumab is administered intranasally, providing a novel approach to immunomodulation for neuroinflammatory diseases.
How can investors request meetings at the conference?
Investors can request one-on-one meetings through the Jefferies conference portal or by contacting Tiziana’s investor relations team.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TLSA Hedge Fund Activity
We have seen 10 institutional investors add shares of $TLSA stock to their portfolio, and 19 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DAUNTLESS INVESTMENT GROUP, LLC added 1,679,043 shares (+96.5%) to their portfolio in Q2 2025, for an estimated $2,652,887
- CITADEL ADVISORS LLC added 198,990 shares (+inf%) to their portfolio in Q2 2025, for an estimated $314,404
- OMERS ADMINISTRATION CORP removed 144,900 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $228,942
- JANE STREET GROUP, LLC removed 142,578 shares (-85.1%) from their portfolio in Q2 2025, for an estimated $225,273
- SIMPLEX TRADING, LLC removed 67,251 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $145,262
- MORGAN STANLEY removed 65,761 shares (-47.3%) from their portfolio in Q2 2025, for an estimated $103,902
- BISON WEALTH, LLC removed 42,795 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $92,437
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
BOSTON, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced that its senior leadership team will present at the prestigious Jefferies London Healthcare Conference.
Chief Executive Officer Ivor Elrifi and Chief Operating Officer/Chief Financial Officer Keeren Shah will deliver a corporate overview highlighting the Company’s innovative pipeline and recent clinical milestones. The session will include an update on the lead candidate foralumab, the only fully human anti-CD3 monoclonal antibody in clinical development administered intranasally for neurodegenerative diseases such as non-active secondary progressive multiple sclerosis (SPMS), Alzheimer’s disease (AD), multiple system atrophy (MSA) and amyotrophic lateral sclerosis (ALS).
The Jefferies London Healthcare Conference is one of Europe’s premier investor forums, attracting leading global healthcare companies, institutional investors, and industry thought leaders. Tiziana’s participation underscores its growing visibility within the biotechnology investment community and its commitment to advancing transformative therapies for patients with high unmet medical needs.
Presentation Details
Event:
Jefferies London Healthcare Conference
Date:
Wednesday, November 19, 2025
Time:
12:30 p.m. – 12:55 p.m. GMT (25-minute presentation)
Location:
London, UK
Presenters:
- Ivor Elrifi, Chief Executive Officer
-
Keeren Shah, Chief Operating Officer and Chief Financial Officer
Management will also be available for one-on-one meetings throughout the conference. Interested parties may request meetings through the Jefferies conference portal or by contacting Tiziana’s investor relations team.
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program ( NCT06802328 ) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis ( NCT06292923 ).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases. [1],[2]
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com .
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email:
[email protected]
[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
